ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Psychiatry · Schizophr Bull · 2026-04-10

In 52 overweight or obese adults with schizophrenia spectrum disorders on atypical antipsychotics, 16 weeks of empagliflozin plus lifestyle intervention reduced body weight (-1.53 kg) and BMI (-0.53 kg/m2) versus placebo; adverse events and dropouts were similar.

RCTn = 52
Wong et al. Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders-A Double-blind Randomized Placebo-controlled Trial
Diabetes and endocrinology · Diabetologia · 2025-12-09

In a randomised cross-over study of 17 participants with non-insulin-treated type 2 diabetes, 5 weeks of empagliflozin vs NPH insulin at similar glucose control gave higher beta cell glucose sensitivity, insulin sensitivity and disposition index.

RCTn = 17
Thirumathyam et al. Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.